# SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

> **NCT06676722** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 20 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)
- SBRT
- Immunotherapy

## Interventions

- **DRUG:** SBRT combined with Nimotuzumab followed by Tislelizumab

## Key facts

- **NCT ID:** NCT06676722
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-05
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06676722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06676722, "SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06676722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*